{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:54:16Z","timestamp":1780678456889,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Concomitant coronary artery disease (CAD) and atrial fibrillation (AF) are common in clinical practice. The aim of this study was to investigate the characteristics and antithrombotic treatment patterns of patients with concomitant CAD and AF from the COhort of antithrombotic use and Optimal INR Level in patients with non-valvular atrial fibrillation in Thailand (COOL-AF Thailand) registry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Registry enrollment criteria included patients aged\u2009\u2265\u200918\u00a0years who were diagnosed with AF for any duration at any of 27 public hospitals located across Thailand during 2014\u20132017. The That Clinical Trials Registry study registration number is TCTR20160113002. Statistical comparisons of characteristics and treatment strategies were performed between patients with and without CAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of a total of 3461 AF patients, 557 had concomitant CAD (16.1%). Patients with concomitant CAD and AF were significantly older, more likely to be male, had more comorbidities, and had more cardiovascular implantable electronic devices. History of stroke\/transient ischemic attack and prior bleeding was not significantly different between groups. CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score and HAS-BLED score were both higher in patients with CAD than in patients without CAD (4.17 <jats:italic>vs.<\/jats:italic> 2.78, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, and 2.01 <jats:italic>vs.<\/jats:italic> 1.45, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, respectively). Utilization of oral anticoagulant was less in patients with CAD (76.0% <jats:italic>vs.<\/jats:italic> 84.3%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Concomitant use of antiplatelet was found to be a major cause of oral anticoagulant (OAC) underutilization. Specifically, the rate of OAC prescription was 95.9% in patients without antiplatelet, and 43.7% in patients with antiplatelet. Among patients with CAD who were on OAC, the rate of concomitant antiplatelet prescription was still high. In this group, 63% of patients were on triple therapy when percutaneous coronary intervention (PCI) with drug eluting stent was performed within 1\u00a0year, and 32.2% of patients without prior PCI or acute coronary syndrome were taking at least one antiplatelet with OAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Among patients with concomitant CAD and AF, physicians were reluctant to discontinue antiplatelet. The use of antiplatelet discourages physicians from prescribing OAC. Underutilization of OAC may increase the risk of ischemic stroke, and an inappropriate combination of OAC and antiplatelet may increase the risk of bleeding.<\/jats:p>\n                <jats:p><jats:italic>Trial registration <\/jats:italic>The trial has been registered with the Thai Clinical Trials Registry (TCTR) which complied with WHO International Clinical Trials Registry Platform dataset. The Registration Number is TCTR20160113002 (05\/01\/2016).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-01928-4","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T13:04:15Z","timestamp":1614690255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailand\u2019s COOL-AF registry"],"prefix":"10.1186","volume":"21","author":[{"given":"Arjbordin","family":"Winijkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontawee","family":"Kaewkumdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahthit","family":"Yindeengam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungroj","family":"Krittayaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"key":"1928_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"1928_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med"},{"key":"1928_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"1928_CR4","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019."},{"key":"1928_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R Sorensen","year":"2009","unstructured":"Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967\u201374.","journal-title":"Lancet"},{"key":"1928_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107\u201315.","journal-title":"Lancet"},{"key":"1928_CR7","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"1928_CR8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"1928_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"RD Lopes","year":"2018","unstructured":"Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open-Label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17\u201323.","journal-title":"Am Heart J"},{"key":"1928_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","volume":"196","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz PE, Eckardt L, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018;196:105\u201312.","journal-title":"Am Heart J"},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/14017430050142198","volume":"34","author":"M Hurlen","year":"2000","unstructured":"Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000;34:168\u201371.","journal-title":"Scand Cardiovasc J"},{"key":"1928_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103\u201313.","journal-title":"N Engl J Med"},{"key":"1928_CR13","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C et al: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020."},{"key":"1928_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4244\/EIJ-D-20-00052","volume":"16","author":"Y Ueki","year":"2020","unstructured":"Ueki Y, Bar S, Losdat S, Otsuka T, Zanchin C, Zanchin T, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020;16:371\u20139.","journal-title":"EuroIntervention"},{"key":"1928_CR15","unstructured":"Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2020."},{"key":"1928_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/eurheartj\/ehy675","volume":"40","author":"F Gragnano","year":"2019","unstructured":"Gragnano F, Calabro P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019;40:216\u20137.","journal-title":"Eur Heart J"},{"key":"1928_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12872-018-0911-4","volume":"18","author":"R Krittayaphong","year":"2018","unstructured":"Krittayaphong R, Winijkul A, Methavigul K, Wongtheptien W, Wongvipaporn C, Wisaratapong T, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord. 2018;18:174.","journal-title":"BMC Cardiovasc Disord"},{"key":"1928_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/2048872618790561","volume":"8","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, et al. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care. 2019;8:176\u201385.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1928_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijcard.2013.10.062","volume":"170","author":"MC Bahit","year":"2013","unstructured":"Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013;170:215\u201320.","journal-title":"Int J Cardiol"},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMoa0803778","volume":"360","author":"SH Hohnloser","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668\u201378.","journal-title":"N Engl J Med"},{"key":"1928_CR21","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825\u201333.","journal-title":"N Engl J Med"},{"key":"1928_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.amjcard.2015.02.003","volume":"115","author":"F D'Ascenzo","year":"2015","unstructured":"D\u2019Ascenzo F, Taha S, Moretti C, Omede P, Grossomarra W, Persson J, et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015;115:1185\u201393.","journal-title":"Am J Cardiol"},{"key":"1928_CR23","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903\u201312.","journal-title":"Lancet"},{"key":"1928_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","volume":"139","author":"Y Matsumura-Nakano","year":"2019","unstructured":"Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139:604\u201316.","journal-title":"Circulation"},{"key":"1928_CR25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J"},{"key":"1928_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154:1121\u2013201.","journal-title":"Chest"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-021-01928-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-01928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T13:11:36Z","timestamp":1614690696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-01928-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-01928-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"25 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the institutional review boards of all participating hospitals. The protocol for this registry was approved by the Central Research Ethics Committee (CREC) for Research in Human Subjects of the Ministry of Public Health, Thailand. Written informed consent was obtained from all included patients prior to participation in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}